Development of a novel bi-specific monoclonal antibody approach for tumour targeting
1999
New Antibody Method for Targeting Tumors
publication
Evidence: moderate
Author Information
Author(s): Koumarianou A A, Hudson M, Williams R, Epenetos A A, Stamp G W H
Primary Institution: Imperial College School of Medicine
Hypothesis
A novel antibody approach has been designed to improve tumour targeting and effector to target ratio.
Conclusion
The new T-cell redirecting approach can effectively kill target cancer cells in vitro.
Supporting Evidence
- Seventy percent lysis was measured in the high MUC1 mucin expressor cell line.
- Forty percent lysis was measured in the low MUC1 mucin expressor cell line.
- No lysis was apparent in the MUC1 negative cell line.
Takeaway
Scientists created a new way to help the immune system find and attack cancer cells better.
Methodology
The study involved using biotinylated anti-CD3 Fab fragments and streptavidinylated anti-tumour monoclonal antibodies to form cross-links for targeting cancer cells.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website